How many insider declarations has Decheng Capital Global Life Sciences Fund IV, L.P. filed?

Decheng Capital Global Life Sciences Fund IV, L.P. has filed 3 public insider declarations with SEC (Form 4).

What is Decheng Capital Global Life Sciences Fund IV, L.P.'s role?

Decheng Capital Global Life Sciences Fund IV, L.P.'s reported role is not specified by the regulator across the filings.

Which companies does Decheng Capital Global Life Sciences Fund IV, L.P. report trades for?

Decheng Capital Global Life Sciences Fund IV, L.P. reports trades for 2 companies, including CG Oncology, Inc..

What is Decheng Capital Global Life Sciences Fund IV, L.P.'s declared buy vs sell volume?

Across the available history, declared buys total 7.0M€ and disposals 0.

← Executives ★ Sign in to follow

DC

Decheng Capital Global Life Sciences Fund IV, L.P.

·SEC (Form 4)

CG Oncology, Inc.Aardvark Therapeutics, Inc.

0

申报总数

0

公司

€701万

▲ 买入（1 笔）

—

▼ 卖出（0 笔）

内部人交易记录

其他

已披露买入

1

已披露卖出

0

T+90 胜率

0%

T+90 平均收益

-10.9%

基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。

信号历史

无可用的信号评分。

Browse the full record of transactions filed by Decheng Capital Global Life Sciences Fund IV, L.P.. Insider active across 2 companies, notably CG Oncology, Inc.. Cumulatively, 3 reports have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €7m. Activity tracked since 29 January 2024. The latest transaction was disclosed on 29 January 2024 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.

Companies and markets linked to Decheng Capital Global Life Sciences Fund IV, L.P.

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

CG Oncology, Inc. (US)Aardvark Therapeutics, Inc. (US)

申报3 总计

●

Decheng Capital Global Life Sciences Fund IV, L.P.

高管2025年2月14日Aardvark Therapeutics, Inc.

0SEC ↗

2,333,887 股Common StockSEC:0000950170-25-023409:0

▲

Decheng Capital Global Life Sciences Fund IV, L.P.

高管2024年1月29日CG Oncology, Inc.

US$760万29SEC ↗

400,000 股@ US$19.00100.0% 占其流量Common StockSEC:0001415889-24-010609:0

标准退出：2024年4月28日 (T+90)

●

Decheng Capital Global Life Sciences Fund IV, L.P.

高管2024年1月29日CG Oncology, Inc.

0SEC ↗

3,628,198 股Common StockSEC:0001415889-24-002062:0

3 条申报中的 3 条

InsidersTradesSigma

← Executives ★ Sign in to follow

DC

Decheng Capital Global Life Sciences Fund IV, L.P.

·SEC (Form 4)

CG Oncology, Inc.Aardvark Therapeutics, Inc.

0

申报总数

0

公司

€701万

▲ 买入（1 笔）

—

▼ 卖出（0 笔）

内部人交易记录

其他

已披露买入

1

已披露卖出

0

T+90 胜率

0%

T+90 平均收益

-10.9%

基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。

信号历史

无可用的信号评分。

Browse the full record of transactions filed by Decheng Capital Global Life Sciences Fund IV, L.P.. Insider active across 2 companies, notably CG Oncology, Inc.. Cumulatively, 3 reports have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €7m. Activity tracked since 29 January 2024. The latest transaction was disclosed on 29 January 2024 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.